Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2026)
Lyell Immunopharma (LYEL) reported Change in Account Payables of $2.4 million for Q1 2026, up 244.07% on a YoY basis from $692581.6 in Q1 2025, and up 633.23% sequentially from $325000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Change in Account Payables data on file, last reported at $2.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 244.07% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 135.56% YoY), and the FY2025 full-year result was -$2.3 million, up 27.67% from the prior year.
- Change in Account Payables advanced to $2.4 million in Q1 2026, from $325000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.9 million in Q1 2022 to a low of -$2.0 million in Q4 2024.
- A 5-year average of -$62294.1 and a median of -$231000.0 in 2025 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 363.25% in 2022 and sank 6230.43% in 2023, its largest moves.
- Tracing LYEL's Change in Account Payables over 5 years: stood at -$526000.0 in 2022, then jumped by 180.8% to $425000.0 in 2023, then tumbled by 579.06% to -$2.0 million in 2024, then soared by 115.96% to $325000.0 in 2025, then soared by 633.23% to $2.4 million in 2026.
- Business Quant data shows LYEL's Change in Account Payables at $2.4 million in Q1 2026, $325000.0 in Q4 2025, and -$779000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | 2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.38 Mn |
| Mar 31, 2026 | 2.38 Mn |
| Dec 31, 2025 | 325,000.00 |
| Dec 31, 2025 | 325,000.00 |
| Sep 30, 2025 | -779,000.00 |
| Sep 30, 2025 | -779,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Jun 30, 2025 | -231,000.00 |
| Mar 31, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.65 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Dec 31, 2024 | -2.04 Mn |
| Sep 30, 2024 | -568,000.00 |
| Sep 30, 2024 | -568,000.00 |
| Jun 30, 2024 | -517,000.00 |
| Jun 30, 2024 | -517,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Mar 31, 2024 | -113,000.00 |
| Dec 31, 2023 | 425,000.00 |
| Dec 31, 2023 | 425,000.00 |